NCT06812871View on ClinicalTrials.gov

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

April 30, 2026

Conditions
Non-small Cell Lung Cancer Metastatic
Interventions
DRUG

furmonertinib

furmonertinib (160mg, once a day, continuous administration); bevacizumab (7.5 mg/kg body weight, once every 3 weeks); Pemetrexed (50 mg intrathecal injection chemotherapy, once every 3 weeks, up to 9 cycles).

Trial Locations (1)

510000

RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER